Key points from article :
Gordian Biotechnology launched with $60 million to develop gene therapies for age-related diseases.
Their platform uses animal models that closely resemble human biology for testing treatments.
Gordian’s method involves introducing a library of gene therapies into a single animal.
Their AI-powered analysis allows them to measure the effectiveness of each therapy.
The platform has shown 80% accuracy in matching preclinical and clinical outcomes.
Currently focusing on 4 age-related diseases: osteoarthritis, metabolic-associated steatohepatitis, heart failure and pulmonary fibrosis.
The company believes their platform can be used for a wide range of diseases associated with aging.
“Gordian is creating a future in which age-related ailments are treated and cured as effectively as infectious diseases today,” - Martin Borch Jensen, CSO of Gordian.
